AOD-9604 · 5 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
AOD9604 5 mg
hGH C-terminal fragment — lipolytic research peptide.
AOD9604 is a modified 15-residue fragment derived from the C-terminus of human growth hormone. Studied for lipolytic research applications.
What the peptide is.
AOD9604 is a modified C-terminal fragment of hGH (residues 176-191), engineered by Metabolic Pharmaceuticals. It was studied in a Phase 2b obesity trial that did not meet its primary endpoint.
The peptide is approved as a food ingredient in some jurisdictions but has no therapeutic approval.
Proposed: direct effects on adipocyte lipolysis, independent of GH receptor signalling.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Standard peptide handling.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT AOD9604 5 mg
DESIGNATION AOD-9604
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.00
MASS EXP. 1815.08 Da
MASS OBS. 1815.10 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for AOD9604 5 mg.
1 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Heffernan M, Summers RJ, Thorburn A, et al.
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Endocrinology · 2001
- Q.Did AOD9604 reach clinical approval?
- A.No — the Phase 2b obesity trial did not meet its primary endpoint. The peptide is used as a preclinical research reagent and has food-ingredient approval in some jurisdictions.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Tesamorelin 10 mg
Approved GHRH analogue — stabilised long-acting GRF(1-44).
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
MOTS-c 40 mg
Mitochondrial-derived 16-residue peptide — high-dose kit.
- Form
- Lyophilised kit
- Dose
- 40 mg / vial
- Purity
- ≥ 99.0%